Dr. Gary Kleiner, MD is an Allergy & Immunology Specialist in Miami, FL, and has over 25 years of experience in the medical field. He graduated from SUNY Downstate M C Coll Med medical school in 1995.
“This is used to hope to prevent the spread of the virus. He was not involved in the trial but in theory because of the high risks of his age and obesity potentially it will offer some benefits,” said Dr. Kleiner.
“This particular trial has a combination of two antibodies, they're what are called non competing, so they're actually working against different parts of the protein. The theory of that is if the virus did mutate against one of them, potentially the other antibody that’s still in the cocktail would still prevent transmission.”
“Most of that data is coming from the treatment studies, not so much the prophylaxis studies, there are patients – particularly young children who might have very high levels in their nose but have very minor symptoms, so the viral load doesn’t necessarily correlate with the symptoms. The studies try to capture both symptoms scores and virus quantitation, so as we learn more about the use of the medications, hopefully, we’ll have better data.”